drugset / Trial / NCT06995339
Comparative Clinical and Biochemical Study Evaluating the Effectiveness of Metformin Versus Febuxostat on Gouty Obese Non-Diabetic Patients
Phase 2
Recruiting
60 enrolled
Mostafa Bahaa
Dalia Naser Abdel-Sadek Safa , Faculty of Pharmacy, Tanta University · collabSahar Mohamed Elhaggar, Faculty of Pharmacy, Tanta University · collabTarek Mohamed Abd-Elazez Nasr-Allah, Faculty of Medicine - Al-Azhar University · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
Gout is a systemic disease that results from the deposition of monosodium urate crystals (MSU) in tissues. Increased serum uric acid (SUA) above a specific threshold (\>6.8 mg/dl) is a requirement for the formation of uric acid crystals. MSU crystals can be deposited in all tissues mainly in and around the joints forming tophi. Early presentation of gout is an acute joint inflammation that is quickly relieved by non-steroidal anti-inflammatory drugs (NSAIDs) or colchicine. Lowering SUA levels below deposition threshold either by dietary modification or using serum uric acid lowering drugs is the main goal in management of gout. This results in dissolution of MSU crystals preventing further attacks
Timeline
- Start
- 2025-05-30
- Primary completion
- 2026-08-20
- Completion
- 2026-12-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Febuxostat | Small molecule | 80 mg | — |
| Comparator | Metformin | Small molecule | 1000 mg | Oral |